NeOnc Technologies Holdings (NTHI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel drug delivery for brain cancers and CNS diseases, with lead candidates NEO100 and NEO212 targeting glioblastoma and other intracranial malignancies.

• NEO100 is in Phase IIa trials for recurrent malignant glioma and meningioma, using intranasal delivery to bypass the blood-brain barrier.

• NEO212, a conjugate of temozolomide and perillyl alcohol, has completed preclinical testing and entered Phase I/II trials for brain tumors and metastases.

• The company holds an exclusive worldwide patent portfolio licensed from USC, covering multiple uses for NEO100, NEO212, and related compounds.

• No commercial products or sales infrastructure; revenue to date is minimal and derived from humanitarian use and licensing.

Financial performance and metrics

• Net loss of $11.9 million in 2024 and $14.9 million in 2023; accumulated deficit of $50.6 million as of December 31, 2024.

• Revenue for 2024 and 2023 was $83,000 and $70,462, respectively, from non-core activities.

• Cash balance at year-end 2024 was $64,893; shareholders' deficit was $5.5 million.

• Research and development expenses increased to $3.0 million in 2024, reflecting expanded clinical activity.

• The company’s auditor included a going concern explanatory paragraph due to recurring losses and limited cash.

Use of proceeds and capital allocation

• The IPO filing registers shares for resale by existing stockholders; the company will not receive proceeds from these sales.

• Recent capital raised through private placements and conversion of debt to equity; additional funding expected from a $10 million line of credit and a $50 million equity purchase agreement.

• Funds are allocated to ongoing clinical trials, regulatory activities, and operational expenses.